标题
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-19
DOI
10.1038/s41416-020-01225-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Top 10 Challenges in Cancer Immunotherapy
- (2020) Priti S. Hegde et al. IMMUNITY
- A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
- (2020) Dimitris Skokos et al. Science Translational Medicine
- Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study
- (2020) Archana Thakur et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Multispecific drugs herald a new era of biopharmaceutical innovation
- (2020) Raymond J. Deshaies NATURE
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
- (2020) Danica Chiu et al. Cancer Immunology Research
- Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
- (2020) Joseph Kauer et al. Journal for ImmunoTherapy of Cancer
- Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
- (2020) Omid Vafa et al. Frontiers in Oncology
- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
- (2020) Yuanyuan Zhang et al. Cellular & Molecular Immunology
- Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
- (2020) Martina Geiger et al. Nature Communications
- Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
- (2020) Priyanka Nair-Gupta et al. Blood Cancer Journal
- Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
- (2020) Iraj Hosseini et al. npj Systems Biology and Applications
- Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
- (2019) Jana de Sostoa et al. Journal for ImmunoTherapy of Cancer
- T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies
- (2019) Belén Blanco et al. TRENDS IN IMMUNOLOGY
- Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
- (2019) Nathan D. Trinklein et al. mAbs
- T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
- (2019) Lin Yu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting Tumor Microenvironment for Cancer Therapy
- (2019) Catarina Roma-Rodrigues et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A coiled-coil masking domain for selective activation of therapeutic antibodies
- (2019) Vivian H. Trang et al. NATURE BIOTECHNOLOGY
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities
- (2019) Xiaoying Chen et al. CTS-Clinical and Translational Science
- Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies
- (2019) Roman H Khadka et al. Immunotherapy
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
- (2019) Christina Claus et al. Science Translational Medicine
- CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
- (2019) Ji Li et al. Science Translational Medicine
- Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells
- (2019) Evelyn Menares et al. Nature Communications
- On-target restoration of a split T cell-engaging antibody for precision immunotherapy
- (2019) Agnes Banaszek et al. Nature Communications
- Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells
- (2019) Beatris Mastelic-Gavillet et al. Journal for ImmunoTherapy of Cancer
- Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
- (2019) Eleanor M. Scott et al. Journal for ImmunoTherapy of Cancer
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- CD103+Tumor-Resident CD8+T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
- (2018) Jarem Edwards et al. CLINICAL CANCER RESEARCH
- Interleukin-10 Directly Inhibits CD8 + T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity
- (2018) Logan K. Smith et al. IMMUNITY
- Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
- (2018) Colin E. Correnti et al. LEUKEMIA
- Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
- (2018) Karie Runcie et al. MOLECULAR MEDICINE
- Targeting Resident Memory T Cells for Cancer Immunotherapy
- (2018) Charlotte Blanc et al. Frontiers in Immunology
- Immune T cells can transfer and boost anti-breast cancer immunity
- (2018) Archana Thakur et al. OncoImmunology
- T lymphocyte subsets in cancer immunity: Friends or foes
- (2018) Dounia Chraa et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
- (2018) Diego Ellerman METHODS
- Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
- (2018) Dionysos Slaga et al. Science Translational Medicine
- The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8 + T cells in the tumor microenvironment
- (2017) Jason B. Williams et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells
- (2017) Michel Enamorado et al. Nature Communications
- Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity
- (2016) Lawrence G. Lum et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- Reversing T-cell Dysfunction and Exhaustion in Cancer
- (2016) H. M. Zarour CLINICAL CANCER RESEARCH
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
- (2016) Jürgen Borlak et al. Oncotarget
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
- (2016) Judith Feucht et al. Oncotarget
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
- (2016) Vita Golubovskaya et al. Cancers
- Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
- (2015) L. G. Lum et al. CLINICAL CANCER RESEARCH
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
- (2015) Kota Iwahori et al. MOLECULAR THERAPY
- Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
- (2015) Bettina Weigelin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
- (2014) Katarzyna Urbanska et al. Journal of Translational Medicine
- Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
- (2014) Irene Michalk et al. PLoS One
- T cell responses: naïve to memory and everything in between
- (2013) Nathan D. Pennock et al. ADVANCES IN PHYSIOLOGY EDUCATION
- CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
- (2013) Lawrence G. Lum et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- CD4+T Cells: Differentiation and Functions
- (2012) Rishi Vishal Luckheeram et al. Clinical & Developmental Immunology
- Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
- (2012) A. Feldmann et al. JOURNAL OF IMMUNOLOGY
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- CD8+ T Cells: Foot Soldiers of the Immune System
- (2011) Nu Zhang et al. IMMUNITY
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
- (2010) Claudia Bluemel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- Tumor Immunotherapy Using Gene-Modified Human Mesenchymal Stem Cells Loaded into Synthetic Extracellular Matrix Scaffolds
- (2008) Marta Compte et al. STEM CELLS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started